284 related articles for article (PubMed ID: 14616425)
1. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.
Allabi AC; Gala JL; Desager JP; Heusterspreute M; Horsmans Y
Br J Clin Pharmacol; 2003 Dec; 56(6):653-7. PubMed ID: 14616425
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.
Bravo-Villalta HV; Yamamoto K; Nakamura K; Bayá A; Okada Y; Horiuchi R
Eur J Clin Pharmacol; 2005 May; 61(3):179-84. PubMed ID: 15776277
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array.
Pickering JW; McMillin GA; Gedge F; Hill HR; Lyon E
Am J Pharmacogenomics; 2004; 4(3):199-207. PubMed ID: 15174901
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
[TBL] [Abstract][Full Text] [Related]
11. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
[TBL] [Abstract][Full Text] [Related]
12. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
14. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
15. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
[TBL] [Abstract][Full Text] [Related]
20. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]